Revumenib Expanded Access Program

Expanded Access Program for SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemias With Genetic Alterations Associated With HOXA Overexpression

What's the purpose of the trial?

This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.

Trial status

Accepting patients

Type

Expanded Access / Compassionate Use

Last Updated

3 months ago

Partner With us to Treat Your Patient's Cancer.

For referring physicians, our dedicated clinician access line can be reached Monday through Friday 8 am to 6pm (Eastern time) by dialing (888) 874-5087.

Refer a Patient Portal Call Clinician Access Line

Participating Centers

There are 7 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Revumenib is a menin inhibitor that may help to slow the growth of different types of cancer cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Revumenib

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.